There is no evidence for an association between the serotonin receptor 3A gene C178T polymorphism and tardive dyskinesia in Korean schizophrenia patients

References

• Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993;19:303–15.
   PubMed Web of Science ®Google Scholar
• Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: Prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8:52S–6S.
   PubMed Web of Science ®Google Scholar
• Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?Mov Disord 2006;21:589–98.
   PubMed Web of Science ®Google Scholar
• Tarsy D, Baldessarini RJ. The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 1977;12:431–50.
   PubMed Web of Science ®Google Scholar
• Hsieh CJ, Chen YC, Lai MS, Hong CJ, Chien KL. Genetic variability in serotonin receptor and transporter genes may influence risk for tardive dyskinesia in chronic schizophrenia. Psychiatry Res 2011;188:175–6.
   PubMed Web of Science ®Google Scholar
• Casey DE, Gerlach J, Magelund G, Christensen TR. gamma- Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry 1980;37:1376–9.
   PubMed Web of Science ®Google Scholar
• Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000;61:525–41.
   PubMed Web of Science ®Google Scholar
• Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiatry 1981;138:1618–9.
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: A study in three rat strains. Psychopharmacology (Berl) 1990;102:474–8.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kang SG. Genetics of tardive dyskinesia. Int Rev Neurobiol 2011;98:231–64.
   PubMed Web of Science ®Google Scholar
• Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41:827–9.
   PubMed Web of Science ®Google Scholar
• Zai CC, De Luca V, Hwang RW, Voineskos A, Muller DJ, Remington G, et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry 2007;12:794–5.
   PubMed Web of Science ®Google Scholar
• Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: A meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008;13:544–56.
   PubMed Web of Science ®Google Scholar
• Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M, et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999;4:247–53.
   PubMed Web of Science ®Google Scholar
• Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139–45.
   PubMed Web of Science ®Google Scholar
• Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, et al. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105–19.
   PubMed Web of Science ®Google Scholar
• de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005;25:448–56.
   PubMed Web of Science ®Google Scholar
• Liao DL, Yeh YC, Chen HM, Chen H, Hong CJ, Tsai SJ. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001;44:95–8.
   PubMed Web of Science ®Google Scholar
• Woo SI, Kim JW, Rha E, Han SH, Hahn KH, Park CS, Sohn JW. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. Psychiatry Clin Neurosci 2002;56:469–74.
   PubMed Web of Science ®Google Scholar
• Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: A meta analysis. Schizophr Res 2006;83:185–92.
   PubMed Web of Science ®Google Scholar
• Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, Lerer B, Deshpande SN, Bk T. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006;16:111–7.
   PubMed Web of Science ®Google Scholar
• Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998;32:101–6.
   PubMed Web of Science ®Google Scholar
• Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T, et al. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 1998; 32:107–13.
   PubMed Web of Science ®Google Scholar
• Lam LC, Garcia-Barcelo MM, Ungvari GS, Tang WK, Lam VK, Kwong SL, et al. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry 2001;34:238–41.
   PubMed Web of Science ®Google Scholar
• Fu Y, Fan CH, Deng HH, Hu SH, Lv DP, Li LH, et al. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 2006;27:328–32.
   PubMed Web of Science ®Google Scholar
• Nikoloff D, Shim JC, Fairchild M, Patten N, Fijal BA, Koch WH, et al. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J 2002;2:400–7.
   PubMedGoogle Scholar
• Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21:106S–15S.
   PubMed Web of Science ®Google Scholar
• Schillevoort I, van Puijenbroek EP, de Boer A, Roos RA, Jansen PA, Leufkens HG. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: A case–control study using spontaneous reports. Int Clin Psychopharmacol 2002;17:75–9.
   PubMed Web of Science ®Google Scholar
• Basile VS, Ozdemir V, Masellis M, Meltzer HY, Lieberman JA, Potkin SG, et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 2001;6:230–4.
   PubMed Web of Science ®Google Scholar
• Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001;6:225–9.
   PubMed Web of Science ®Google Scholar
• Tan EC, Chong SA, Mahendran R, Dong F, Tan CH. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol Psychiatry 2001;50:144–7.
   PubMed Web of Science ®Google Scholar
• Herken H, Erdal ME, Böke Ö, Savas HA. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene. Eur Psychiat 2003;18:77–81.
   PubMed Web of Science ®Google Scholar
• Chong SA, Tan EC, Tan CH, Mahendren R, Tay AH, Chua HC. Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese. Am J Med Genet 2000;96:712–5.
   PubMed Web of Science ®Google Scholar
• Guertin PA, Steuer I. Ionotropic 5-HT3 receptor agonist-induced motor responses in the hindlimbs of paraplegic mice. J Neurophysiol 2005;94:3397–405.
   PubMed Web of Science ®Google Scholar
• Toren P, Laor N, Cohen DJ, Wolmer L, Weizman A. Ondansetron treatment in patients with Tourette's syndrome. Int Clin Psychopharmacol 1999;14:373–6.
   PubMed Web of Science ®Google Scholar
• Toren P, Weizman A, Ratner S, Cohen D, Laor N. Ondansetron treatment in Tourette's disorder: A 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2005;66:499–503.
   PubMed Web of Science ®Google Scholar
• Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083–152.
   PubMed Web of Science ®Google Scholar
• Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 1991;254:432–7.
   PubMed Web of Science ®Google Scholar
• Gu B, Wang L, Zhang AP, Ma G, Zhao XZ, Li HF, et al. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenet Genomics 2008;18:721–7.
   PubMed Web of Science ®Google Scholar
• Frank B, Niesler B, Nothen MM, Neidt H, Propping P, Bondy B, et al. Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet 2004;131B:1–5.
   PubMed Web of Science ®Google Scholar
• Niesler B, Weiss B, Fischer C, Nothen MM, Propping P, Bondy B, et al. Serotonin receptor gene HTR3A variants in schizophrenic and bipolar affective patients. Pharmacogenetics 2001;11:21–7.
   PubMedGoogle Scholar
• Niesler B, Flohr T, Nothen MM, Fischer C, Rietschel M, Franzek E, et al. Association between the 5’ UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics 2001;11:471–5.
   PubMedGoogle Scholar
• Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 2010;20:274–6.
   PubMed Web of Science ®Google Scholar
• Ji X, Takahashi N, Saito S, Ishihara R, Maeno N, Inada T, Ozaki N. Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population. Neurosci Lett 2008;435:95–8.
   PubMed Web of Science ®Google Scholar
• Han OS, Hong JP. Structured Clinical Interview for DSM-IV Axis I Disorder–Korean Version. Seoul: Hana Medical Publishing; 2000.
   Google Scholar
• Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, 1976, p. 534–7.
   Google Scholar
• Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486–7.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kang SG, Choi JE, Paik JW, Kim YK, Kim SH, et al. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia. Neuropsychobiology 2007;55:47–51.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kang SG, Paik JW, Lee MS, Cho BH, Park YM, et al. No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia. Hum Psychopharmacol 2007;22:501–4.
   PubMed Web of Science ®Google Scholar
• Kang SG, Choi JE, An H, Lim SW, Lee HJ, Han C, et al. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1545–8.
   PubMed Web of Science ®Google Scholar
• Kang SG, Choi JE, An H, Park YM, Lee HJ, Han C, et al. Manganese superoxide dismutase gene Ala–9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1844–7.
   PubMed Web of Science ®Google Scholar
• Kang SG, Choi JE, Park YM, Lee HJ, Han C, Kim YK, et al. Val158Met polymorphism in the catechol-O-methyltransferase (COMT) gene is not associated with tardive dyskinesia in schizophrenia. Neuropsychobiology 2008;57:22–5.
   PubMed Web of Science ®Google Scholar
• Kang SG, Lee HJ, Choi JE, An H, Rhee M, Kim L. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. Hum Psychopharmacol 2009;24:55–60.
   PubMed Web of Science ®Google Scholar
• Park YM, Kang SG, Choi JE, Kim YK, Kim SH, Park JY, et al. No evidence for an association between dopamine D2 receptor polymorphisms and tardive dyskinesia in Korean schizophrenia patients. Psychiatry Investig 2011;8:49–54.
   PubMed Web of Science ®Google Scholar
• Kim IS, Yoon HK, Kang SG, Park YM, Kim YK, Kim SH, et al. No association between PAWR gene polymorphisms and tardive dyskinesia in schizophrenia patients. Psychiatry Investig 2012;9:191–4.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kang SG, Choi JE, Park YM, Lim SW, Rhee MK, et al. No evidence for association between tyrosine hydroxylase gene Val81Met polymorphism and susceptibility to tardive dyskinesia in schizophrenia. Psychiatry Investig 2009;6:108–11.
   PubMed Web of Science ®Google Scholar
• Niesler B, Frank B, Hebebrand J, Rappold G. Serotonin receptor genes HTR3A and HTR3B are not involved in Gilles de la Tourette syndrome. Psychiatr Genet 2005;15:303–4.
   PubMed Web of Science ®Google Scholar
• Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000;152:408–13.
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Zhang XB, Sha WW, Reynolds GP. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 2002;7:670–1.
   PubMed Web of Science ®Google Scholar
• Deshpande SN, Varma PG, Semwal P, Rao AR, Bhatia T, Nimgaonkar VL, et al. II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatr Genet 2005;15:157–8.
   PubMed Web of Science ®Google Scholar
• Rietschel M, Naber D, Fimmers R, Moller HJ, Propping P, Nothen MM. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 1997;8:1999–2003.
   PubMed Web of Science ®Google Scholar
• Han GR, Lee YW, Lee HL, Kim SM, Ku TW, Kang IH, et al. A Korean population study of the nine STR loci FGA, VWA, D3S1358, D18S51, D21S11, D8S1179, D7S820, D13S317 and D5S818. Int J Legal Med 2000;114:41–4.
   PubMed Web of Science ®Google Scholar